0001193125-20-031473.txt : 20200211 0001193125-20-031473.hdr.sgml : 20200211 20200211170032 ACCESSION NUMBER: 0001193125-20-031473 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200211 DATE AS OF CHANGE: 20200211 EFFECTIVENESS DATE: 20200211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Insys Therapeutics, Inc. CENTRAL INDEX KEY: 0001516479 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510327886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-35902 FILM NUMBER: 20597899 BUSINESS ADDRESS: STREET 1: 10220 SOUTH 51ST STREET STREET 2: SUITE 2 CITY: PHOENIX STATE: AZ ZIP: 85044 BUSINESS PHONE: 602-910-2617 MAIL ADDRESS: STREET 1: 10220 SOUTH 51ST STREET STREET 2: SUITE 2 CITY: PHOENIX STATE: AZ ZIP: 85044 15-12B 1 d884224d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number:  001-35902

 

 

INSYS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

3100 West Ray Road Ste. 201

Chandler, Arizona 85226

(480) 500-3127

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.01 par value per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   ☒

Rule 12g-4(a)(2)

   ☐

Rule 12h-3(b)(1)(i)

   ☐

Rule 12h-3(b)(1)(ii)

   ☐

Rule 15d-6

   ☒

Rule 15d-22(b)

   ☐

Approximate number of holders of record as of the certification or notice date: 95

Pursuant to the requirements of the Securities Exchange Act of 1934, Insys Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:   February 11, 2020   By:  

/s/ Andrece Housley

     

Name: Andrece Housley

     

Title: Chief Financial Officer